MCID: GLL048
MIFTS: 46

Glial Tumor

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Glial Tumor

MalaCards integrated aliases for Glial Tumor:

Name: Glial Tumor 58
Glioma 58

Characteristics:

Orphanet epidemiological data:

58
glial tumor
Prevalence: 1-9/100000 (United States),1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

MESH via Orphanet 44 D005910
UMLS via Orphanet 72 C0017638
Orphanet 58 ORPHA182067

Summaries for Glial Tumor

MalaCards based summary : Glial Tumor, also known as glioma, is related to brain stem glioma and glioma susceptibility 1. An important gene associated with Glial Tumor is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Central carbon metabolism in cancer. The drugs Midazolam and Trametinib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are growth/size/body region and respiratory system

Wikipedia : 74 Glial tumor is a general term for numerous tumors of the central nervous system (CNS), including... more...

Related Diseases for Glial Tumor

Diseases related to Glial Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1099)
# Related Disease Score Top Affiliating Genes
1 brain stem glioma 33.3 PTEN OLIG2 IDH1
2 glioma susceptibility 1 31.7 PTEN OLIG2 IDH1
3 medulloblastoma 31.3 PTEN MMP9 IDH1
4 glioma 30.4 PTEN MMP9 IDH1
5 dysembryoplastic neuroepithelial tumor 30.2 OLIG2 IDH1
6 arteriovenous malformation 30.1 PTEN MMP9
7 glioblastoma multiforme 30.1 PTEN MMP9 IDH1
8 oligodendroglioma 30.0 PTEN OLIG2 IDH1
9 li-fraumeni syndrome 29.9 PTEN IDH1
10 childhood oligodendroglioma 29.8 OLIG2 IDH1
11 high-grade astrocytoma 29.8 PTEN IDH1
12 supratentorial cancer 29.8 OLIG2 IDH1
13 central nervous system cancer 29.7 PTEN OLIG2 IDH1
14 chordoma 29.6 PTEN IDH1
15 hemangioma 29.6 PTEN MMP9 IDH1
16 gemistocytic astrocytoma 29.5 PTEN IDH1
17 giant cell glioblastoma 29.5 PTEN OLIG2 IDH1
18 gliomatosis cerebri 29.5 PTEN IDH1
19 mixed glioma 29.4 PTEN OLIG2 IDH1
20 juvenile pilocytic astrocytoma 29.4 PTEN OLIG2 IDH1
21 clear cell ependymoma 29.4 OLIG2 IDH1
22 brain cancer 29.4 PTEN OLIG2 IDH1
23 intrahepatic cholangiocarcinoma 29.4 PTEN IDH1
24 grade iii astrocytoma 29.3 PTEN OLIG2 MMP9 IDH1
25 lung cancer susceptibility 3 29.3 PTEN MMP9 IDH1
26 fibrillary astrocytoma 29.2 PTEN OLIG2 IDH1
27 meningioma, familial 29.1 PTEN OLIG2 MMP9 IDH1
28 myeloma, multiple 29.1 PTEN MMP9 IDH1
29 tongue cancer 29.1 PTEN MMP9
30 myelodysplastic syndrome 29.0 PTEN MMP9 IDH1
31 cholangiocarcinoma 28.9 PTEN MMP9 IDH1
32 gliosarcoma 28.8 PTEN OLIG2 MMP9 IDH1
33 tongue squamous cell carcinoma 28.4 PTEN MMP9
34 osteoporosis 27.8 PTEN MMP9 CA2
35 diffuse intrinsic pontine glioma 12.6
36 optic nerve glioma 12.6
37 glioma susceptibility 9 12.6
38 glioma susceptibility 3 12.6
39 optic pathway glioma 12.5
40 glioma susceptibility 2 12.5
41 childhood brain stem glioma 12.5
42 mixed neuronal-glial tumor 12.4
43 subependymal glioma 12.3
44 glial tumor of neuroepithelial tissue with unknown origin 12.3
45 childhood optic nerve glioma 12.3
46 glioma susceptibility 6 12.3
47 glioma susceptibility 8 12.3
48 glioma susceptibility 5 12.3
49 glioma susceptibility 7 12.2
50 glioma susceptibility 4 12.2

Graphical network of the top 20 diseases related to Glial Tumor:



Diseases related to Glial Tumor

Symptoms & Phenotypes for Glial Tumor

MGI Mouse Phenotypes related to Glial Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.55 CA2 IDH1 MMP9 OLIG2 PTEN
2 respiratory system MP:0005388 9.35 CA2 IDH1 MMP9 OLIG2 PTEN
3 skeleton MP:0005390 9.02 CA2 IDH1 MMP9 OLIG2 PTEN

Drugs & Therapeutics for Glial Tumor

Drugs for Glial Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 570)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Trametinib Approved Phase 4 871700-17-3 11707110
3
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
4
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
5 Anti-Anxiety Agents Phase 4
6 Excitatory Amino Acid Antagonists Phase 4
7 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
8
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
11
Carmustine Approved, Investigational Phase 3 154-93-8 2578
12
Dalteparin Approved Phase 3 9005-49-6
13
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
14
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
17
Trioxsalen Approved Phase 3 3902-71-4 5585
18
Donepezil Approved Phase 3 120014-06-4 3152
19
Thioguanine Approved Phase 3 154-42-7 2723601
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
22
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
23
Ethanol Approved Phase 2, Phase 3 64-17-5 702
24
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
25
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
26
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
27
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
28
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
29
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
30
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
31
Etoposide Approved Phase 3 33419-42-0 36462
32
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
33
Histamine Approved, Investigational Phase 3 51-45-6 774
34
leucovorin Approved Phase 3 58-05-9 6006 143
35
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
36
Cyproheptadine Approved Phase 3 129-03-3 2913
37
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
38
Norepinephrine Approved Phase 3 51-41-2 439260
39
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
40
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
42 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
43 Dianhydrogalactitol Investigational Phase 3 23261-20-3
44 Cola Phase 3
45 Heparin, Low-Molecular-Weight Phase 3
46 calcium heparin Phase 3
47 Endothelial Growth Factors Phase 2, Phase 3
48 Anesthetics Phase 3
49 Anti-Inflammatory Agents, Non-Steroidal Phase 3
50 Analgesics, Non-Narcotic Phase 3

Interventional clinical trials:

(show top 50) (show all 1393)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
4 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
5 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
6 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
7 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
8 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
9 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
10 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
11 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
12 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
13 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
14 A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
15 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
16 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
17 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
18 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
19 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
20 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
21 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
22 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
23 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
24 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
25 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
26 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
27 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
28 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
29 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
30 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
31 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
32 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
33 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
34 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
35 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
36 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
37 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
38 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
39 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
40 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
41 A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Completed NCT00561990 Phase 2, Phase 3 Nimotuzumab
42 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
43 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
44 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
45 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
46 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Recruiting NCT04164901 Phase 3 AG-881;Matching Placebo
47 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
48 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
49 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
50 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine

Search NIH Clinical Center for Glial Tumor

Genetic Tests for Glial Tumor

Anatomical Context for Glial Tumor

MalaCards organs/tissues related to Glial Tumor:

40
Brain, T Cells, Endothelial, Spinal Cord, Bone, Testes, Retina

Publications for Glial Tumor

Articles related to Glial Tumor:

(show top 50) (show all 30453)
# Title Authors PMID Year
1
A novel germline mutation of PTEN associated with brain tumours of multiple lineages. 6 61
12085208 2002
2
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 6
16825431 2007
3
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 6
15689453 2005
4
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 6
14670928 2004
5
Gambogic Acid Affects Ribosomal Occurrence in Glioma Cells by Downregulating the Phosphoinositide Kinase-3/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway. 61
31748028 2020
6
Prolonged tracheal extubation time after glioma surgery was associated with lack of familiarity between the anesthesia provider and the operating neurosurgeon. A retrospective, observational study. 61
31669746 2020
7
The long noncoding RNA ZFAS1 promotes the progression of glioma by regulating the miR-150-5p/PLP2 axis. 61
31535380 2020
8
A negative feedback loop of H19/miR-675/VDR mediates therapeutic effect of cucurmin in the treatment of glioma. 61
31468534 2020
9
Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. 61
31848230 2020
10
MicroRNA-519d-3p inhibits cell proliferation and cell cycle G1/S transition in glioma by targeting CCND1. 61
31661371 2020
11
LncRNA PCED1B-AS1 activates the proliferation and restricts the apoptosis of glioma through cooperating with miR-194-5p/PCED1B axis. 61
31680313 2020
12
Current Role of Radiation Therapy in the Management of Malignant Central Nervous System Tumors. 61
31739940 2020
13
Umbilical cord-derived mesenchymal stromal/stem cells expressing IL-24 induce apoptosis in gliomas. 61
31301067 2020
14
Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. 61
30963577 2020
15
New trends in glioma cancer therapy: Targeting Na+ /H + exchangers. 61
31250444 2020
16
Effect of Hydroxyethyl Starch Loading on Glycocalyx Shedding and Cerebral Metabolism During Surgery. 61
31614325 2020
17
Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment. 61
31689562 2020
18
Large and small extracellular vesicles released by glioma cells in vitro and in vivo. 61
31839905 2020
19
Evaluation of Genetic Variants in MIR3142HG in Susceptibility to and Prognosis of Glioma. 61
31513017 2020
20
Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors. 61
31595628 2020
21
A new molecular probe: An NRP-1 targeting probe for the grading diagnosis of glioma in nude mice. 61
31705924 2020
22
Repeatability of amide proton transfer-weighted signals in the brain according to clinical condition and anatomical location. 61
31338651 2020
23
PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. 61
31819973 2020
24
The Application of FOXO1A Expression Predicts Aggressive Behavior and Poor Prognosis in Gliomas. 61
30664534 2020
25
Methods for Evaluation of a Snake Venom-Derived Disintegrin in Animal Models of Human Cancer. 61
31576529 2020
26
Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma. 61
31810002 2020
27
Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside. 61
31241171 2020
28
18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence. 61
31162269 2020
29
The influence of patient sex on clinical approaches to malignant glioma. 61
31605777 2020
30
Long noncoding RNA HAS2-AS1 promotes tumor progression in glioblastoma via functioning as a competing endogenous RNA. 61
31385362 2020
31
Altered hemodynamics contribute to local but not remote functional connectivity disruption due to glioma growth. 61
30334672 2020
32
CircZNF609/miR-134-5p/BTG-2 axis regulates proliferation and migration of glioma cell. 61
31721211 2020
33
Effects of dexmedetomidine on glioma cells in the presence or absence of cisplatin. 61
31452248 2020
34
Quantitative vs. semiquantitative assessment of intratumoral susceptibility signals in patients with different grades of glioma. 61
31087724 2020
35
Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis. 61
31211412 2020
36
Ibuprofen induces ferroptosis of glioblastoma cells via downregulation of nuclear factor erythroid 2-related factor 2 signaling pathway. 61
31490283 2020
37
PABPC1 relevant bioinformatic profiling and prognostic value in gliomas. 61
31797689 2020
38
Overexpression of circular RNA circ-CDC45 facilitates glioma cell progression by sponging miR-516b and miR-527 and predicts an adverse prognosis. 61
31407396 2020
39
3-Bromopyruvate inhibits the malignant phenotype of malignantly transformed macrophages and dendritic cells induced by glioma stem cells in the glioma microenvironment via miR-449a/MCT1. 61
31710894 2020
40
Perinatal complex low- and high-grade glial tumor harboring a novel GIGYF2-ALK fusion. 61
31556208 2020
41
Diffuse Midline Glioma H3 K27M-Mutant Manifested as Progressive Paraplegia. 61
31839872 2020
42
EX527, a Sirt-1 inhibitor, induces apoptosis in glioma via activating the p53 signaling pathway. 61
31490284 2020
43
Normalization in Human Glioma Tissue. 61
31578695 2020
44
Larotrectinib imaging response in low-grade glioma. 61
31544356 2020
45
A novel lncRNA-LINC01116 regulates tumorigenesis of glioma by targeting VEGFA. 61
31144303 2020
46
Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity. 61
31690954 2019
47
Mutant-allele tumor heterogeneity in malignant glioma effectively predicts neoplastic recurrence. 61
31788085 2019
48
IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells. 61
31638255 2019
49
Association of Glioma Grading With Inflow-Based Vascular-Space-Occupancy MRI: A Preliminary Study at 3T. 61
30932289 2019
50
Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma. 61
30977078 2019

Variations for Glial Tumor

ClinVar genetic disease variations for Glial Tumor:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 subset of 188 genes: ELAVL2 , HNRNPK complex Likely pathogenic 617751 9:23524426-87359888

Expression for Glial Tumor

Search GEO for disease gene expression data for Glial Tumor.

Pathways for Glial Tumor

Pathways related to Glial Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.29 PTEN IDH1 CA2
2 10.79 PTEN IDH1

GO Terms for Glial Tumor

Cellular components related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ficolin-1-rich granule lumen GO:1904813 8.96 MMP9 IDH1
2 tertiary granule lumen GO:1904724 8.62 MMP9 IDH1

Biological processes related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.26 PTEN IDH1
2 response to organic substance GO:0010033 9.16 PTEN CA2
3 response to steroid hormone GO:0048545 8.96 IDH1 CA2
4 response to zinc ion GO:0010043 8.62 PTEN CA2

Sources for Glial Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....